Sensitivity of short-term cultures derived from human malignant glioma to the anti-cancer drug temozolomide

Anti-Cancer Drugs

Volumn 10, Issue 2, 1999, Pages 179-185

  Sankar, A ^a,b   Thomas, D G T ^a   Darling, J L ^a  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

CCNU; Chemosensitivity; Glioma; O6 alkylguanine DNA alkyltransferase; Temozolomide

Indexed keywords

LOMUSTINE; TEMOZOLOMIDE;

ARTICLE; ASTROCYTOMA; BLADDER CARCINOMA; CANCER CELL CULTURE; CELL SURVIVAL; COLON CARCINOMA; CONTROLLED STUDY; CROSS RESISTANCE; DRUG RESISTANCE; DRUG SENSITIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MONOLAYER CULTURE; PRIORITY JOURNAL; TESTIS TERATOMA;

EID: 0032999581     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-199902000-00006     Document Type: Article

References (31)

1. Stenning SP, Freedman LS, Bleehen NM. An overview of published results from randomized studies of nitrosoureas in primary high grade malignant glioma. Br J Cancer 1987; 56: 89-90.
2. Fine H, Dear L, Loeffler J, et al. Meta-analysis of radiation therapy with or without adjuvant chemotherapy for malignant gliomas in adults. Cancer 1992; 71: 2585-97.
3. Berger MS, Leibel SA, Bruner JM, et al. Primary central nervous system tumors of the supratentorial compartment. In: Levin VA, ed. Cancer in the nervous system. New York: Churchill Livingstone 1996: 57-126.
4. Newlands ES, Stevens MFG, Wedge SR, et al. Temozolomide: a review of its discovery, chemical properties, preclinical development and clinical trials. Cancer Treat Rev 1997; 23: 35-61.
5. Plowman J, Waud WR, Koutsoukos AD, et al. Preclinical antitumor activity of temozolomide in mice: efficacy against human brain xenografts and synergism with 1,3-bis (2-chloroethyl)-1-nitrosourea. Cancer Res 1994; 54: 3793-9.
6. Friedman HS, Dolan ME, Pegg AE, et al. Activity of temozolomide in the treatment of central nervous system tumor xenografts. Cancer Res 1995; 55: 2853-7.
7. Newlands ES, Blackledge GRP, Slack JA, et al. Phase I trial of temozolomide (CRG 81045; MB 39831; NSC 362856). Br J Cancer 1992; 65: 287-91.
8. O'Reilly S, Newlands E, Glaser M, et al. Temozolomide; a new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumours. Eur J Cancer 1993; 29: 940-2.
9. Bower M, Newlands ES, Bleehen NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997; 40: 484-8.
10. Freshney R. Tissue culture of glioma of the brain. In: Thomas DGT, Graham DI, eds. Brain tumours: scientific basis, clinical investigation and current therapy. London: Butterworths 1980: 21-50.
11. Darling JL. The in vitro biology of human brain tumours. In: Thomas DGT ed. Neuro-oncology: primary malignant brain tumours. London: Edward Arnold 1990: 1-25.
12. Darling JL. Brain In: Masters JRW. Human cancer in primary culture: a handbook. Dordrecht: Kluwer 1991: 231-51.
13. Thomas DGT, Darling JL, Paul EA, et al. Assay of anticancer drugs in tissue culture: Relationship of relapse free interval (RFT) and in vitro chemosensitivity in patients with malignant cerebral glioma. Br J Cancer 1985; 51: 525-32.
14. Darling JL, Lewandowicz GM, Thomas DGT. Chemosensitivity testing human malignant brain tumors. In: Kornblith PL, Walker MD, eds. Advances in neuro-oncology II. Armonk, NY: Futura 1997: 413-34.
15. 35S-methionine uptake assay. Regional Cancer Chemother 1989; 2: 112-8.
16. Haselsberger K, Peterson DC, Thomas. DGT, et al. Assay of anticancer drugs in tissue culture: Comparison of a tetrazolium-based assay and a protein binding dye assay in short-term cultures derived from human malignant glioma. Anti-Cancer Drugs 1996; 7: 331-8.
17. 6-alkylguanine-DNA alkyl transferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br J Cancer 1993; 67: 1299-302.
18. Liu L, Markowilz S, Gerson SL. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not 1,3-bis (2-chloroethyl) nitrosourea. Cancer Res 1996; 56: 5375-9.
19. Devineni D, Klein-Szanto A, Gallo JM. Uptake of temozolomide in a rat glioma model in the presence of the angiogenesis inhibitor TNP-470. Cancer Res 1996; 56: 1983-7.
20. Meikle SR, Matthews JC, Brock CS, et al. Pharmacokinetic assessment of novel anti-cancer drugs using spectral analysis and positron emission tomography: A feasibility study. Cancer Chemother Pharmacol 1998; 42: 183-93.
21. Kimmel DW, Shapiro JR, Shapiro WR. In vitro drug sensitivity testing in human gliomas. J Neurosurg 1987; 66: 161-71.
22. 6-akylguanine DNA adducts in glioma-derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea. Carcinogenesis 1986; 7: 879-83.
23. 6-alkylguanine-DNA alkyl-transferase. Br J Cancer 1997; 75: 500-5.
24. Belanich M, Pastor M, Randall T, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996; 56: 783-8.
25. 6-benzylguanine: a comparative study in vitro. Br J Cancer 1996; 73: 482-90.
26. Friedman HS, Johnson SP, Dong Q, et al. Methylator resistance mediated by mismatch repair deficiency in a glioblastoma xenograft. Cancer Res. 1997; 57: 2933-6.
27. Dams E, Van de Kelft EJ, Martin JJ, et al. Instability of microsatellites in human gliomas. Cancer Res 1995; 55: 1547-9.
28. Wei Q, Bondy ML, Mao L, et al. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res 1997; 57: 1673-7.
29. 6-alkylguanine DNA-alkyltransferase is not a major determinant of sensitivity to 1,3-bis(2-chloroethyl)-1-nitrosourea in four medulloblastoma cell lines. Oncol Res 1992; 4: 241-8.
30. Morgan D, Freshney RI, Darling JL, et al. Assay of anticancer drugs in tissue culture: cell cultures from biopsies of human astrocytoma. Br J Cancer 1983; 47: 205-14.
31. Pera MF, Koberle B, Masters JRW. Exceptional sensitivity of testicular germ cell tumour cell lines to the anti-cancer agent, temozolomide. Br J Cancer 1995; 71: 904-6.